We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




International Gene Mapping Study Identifies More Genes Linked to Cardiovascular Disease Risk

By LabMedica International staff writers
Posted on 20 Dec 2012
A large study focusing on the genetics of cardiovascular disease (CAD) identified several significant molecular pathways mapping to networks linked to lipid metabolism and inflammation, underscoring the causal role of these activities in the genetic etiology of CAD.

The study was carried out under the aegis of the CARDIoGRAMplusC4D (Coronary ARtery DIsease Genome-wide Replication and Meta-analysis plus The Coronary Artery Disease) consortium, hosted by the Wellcome Trust Sanger Institute (Hinxton, United Kingdom). More...
This consortium represents a collaborative effort to combine data from multiple large-scale genetic studies to identify risk loci for coronary artery disease and myocardial infarction.

The latest study from the CARDIoGRAMplusC4D Consortium combined the efforts of 180 researchers from countries across Europe (United Kingdom, Germany, Iceland, Sweden, Finland, The Netherlands, France, Italy, and Greece) as well as Lebanon, Pakistan, Korea, USA, and Canada. These laboratories analyzed DNA samples from more than 60,000 CAD cases and 130,000 normal controls.

Results published in the December 2, 2012, online edition of the journal Nature Genetics identified 15 genetic regions newly associated with the disease, bringing to 46 the number of regions associated with CAD risk. A further 104 independent variants strongly associated with CAD were found, which account for approximately 10.6% of inherited CAD genes. The four most significant pathways mapping to these networks were linked to lipid metabolism and inflammation, underscoring the causal role of these activities in the genetic etiology of CAD.

Of the 46 genome-wide significant lead single-nucleotide polymorphisms (SNPs), 12 showed a significant association with a lipid trait, and five showed a significant association with blood pressure, but none was significantly associated with diabetes.

"The importance of the work is that while some of the genetic variants that we have identified work through known risk factors for CAD such as high blood pressure and cholesterol, many of the variants appear to work through unknown mechanisms," said senior author Dr. Nilesh Samani, professor of cardiology at the University of Leicester (United Kingdom). "Understanding how these genetic variants affect CAD risk is the next goal and this could pave a way to developing new treatments for this important disease."

Related Links:

Wellcome Trust Sanger Institute
University of Leicester



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.